Scarica l'app Stockscreener
49.26
0.50%
-0.25
Dopo l'orario di chiusura:
49.26
Precedente Chiudi:
$49.51
Aprire:
$49.82
Volume 24 ore:
3.33M
Relative Volume:
1.54
Capitalizzazione di mercato:
$9.15B
Reddito:
$2.69B
Utile/perdita netta:
$-214.04M
Rapporto P/E:
-42.10
EPS:
-1.17
Flusso di cassa netto:
$98.43M
1 W Prestazione:
-0.10%
1M Prestazione:
-9.21%
6M Prestazione:
-17.46%
1 anno Prestazione:
-22.17%
Intervallo 1D:
$48.76
$50.98
Intervallo di 1 settimana:
$45.94
$51.45
Portata 52W:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
49.26 | 9.15B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
Exact Sciences Corp Earnings Call Highlights Growth - TipRanks
Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline - Morningstar
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
TD Cowen sees upside in Exact Sciences stock, maintains $86 target - Investing.com
Exact Sciences stock price target cut to $65 at BTIG - Investing.com
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript - Insider Monkey
Exact Sciences stock price target cut to $65 at BTIG By Investing.com - Investing.com South Africa
Exact Sciences Reports Robust Q4 Earnings, Surpassing Revenue ProjectionsNews and Statistics - IndexBox, Inc.
Exact Sciences (EXAS) PT Lowered to $65 at BTIG - StreetInsider.com
Exact Sciences: Q4 Earnings Snapshot - mySA
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences Reports Strong Revenue Growth in 2024 - TipRanks
Exact Sciences 2025 revenue guidance range includes consensus - MSN
Exact Sciences Announces Fourth Quarter 2024 Results - BioSpace
Exact Sciences Corp reports results for the quarter ended December 31Earnings Summary - TradingView
EXACT SCIENCES Earnings Results: $EXAS Reports Quarterly Earnings - Nasdaq
Exact Sciences Corp Plans To Launch Three New Cancer Tests In 2025 -February 19, 2025 at 05:44 pm EST - Marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Stock Slides On Q4 Earnings: The Details - Benzinga
Exact Sciences stock falls despite Q4 earnings beat By Investing.com - Investing.com Australia
Exact Sciences stock falls despite Q4 earnings beat - Investing.com
Exact Sciences: Q4 Earnings Snapshot -February 19, 2025 at 04:43 pm EST - Marketscreener.com
Exact Sciences Q4 Net Loss Widens, Revenue Up; Sets Outlook -February 19, 2025 at 04:22 pm EST - Marketscreener.com
EXACT Sciences earnings beat by $0.27, revenue topped estimates - Investing.com
Exact Sciences Corp. Reports Fourth Quarter and Full Year 2024 Results - TradingView
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of a Second Patent Asserted by Exact Sciences - Business Wire
Banque Pictet & Cie SA Has $3.97 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (EXAS) Projected to Post Earnings on Wednesday - MarketBeat
8,508 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors - MarketBeat
Barclays sets Exact Sciences stock price target at $70 with Overweight rating - MSN
abrdn plc Grows Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
EULAV Asset Management Sells 20,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Thompson Investment Management Inc. Buys 36,505 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
When Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Position Cut by Jennison Associates LLC - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Swedbank AB Buys 13,333 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Receives $72.76 Average Price Target from Brokerages - MarketBeat
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing - BioSpace
Blue Trust Inc. Reduces Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Boosted by Chicago Capital LLC - MarketBeat
Gagnon Securities LLC Has $13.83 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences' Cologuard gets FDA committee nod - WiscNews
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call - BioSpace
Earnings Alert: Exact Sciences Q4 2024 Results Coming February 19What Wall Street Is Watching - StockTitan
77,053 Shares in Exact Sciences Co. (NASDAQ:EXAS) Purchased by Baader Bank Aktiengesellschaft - MarketBeat
Barclays Initiates Coverage of Exact Sciences (EXAS) with Overweight Recommendation - MSN
Exact Sciences Co. (NASDAQ:EXAS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
3.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):